Login to Your Account



Other News To Note


Wednesday, October 3, 2012
• Amakem NV, of Diepenbeek, Belgium, initiated a Phase IIa proof-of-concept study of its Rho kinase (ROCK) inhibitor, AMA0076, in patients with glaucoma and ocular hypertension.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription